Wellspring Longevity Clinic review

Wellspring is two sites in one tone. Its longevity shelf is direct: sermorelin, NAD⁺ and glutathione each get a named treatment page, and the sourcing disclosure is exactly right — medication is compounded and dispensed by a licensed third-party pharmacy, and Wellspring states it is neither a pharmacy nor a manufacturer. Its weight-loss half is the opposite, marketing semaglutide as "Personalized GLP-1" and tirzepatide as "GLP-1/GIP" rather than naming either. Neither half publishes a price. Add leftover template pages sitting in its own navigation and the site looks unfinished.

Wellspring Longevity Clinic is a California-based longevity telehealth service offering compounded GLP-1 therapy for weight management alongside a wellness menu of NAD⁺, sermorelin, glutathione, hormone replacement therapy and GLP-1 microdosing. Its stated path is straightforward: choose a treatment, complete an online intake, consult a licensed provider, receive medication by mail. It publishes a full legal suite — terms of use, privacy policy, returns and refunds, a California privacy notice and a HIPAA notice — with California governing law and arbitration in San Diego.

Asynchronous intake with provider review, and a clear sourcing disclosure. In its own words on the GLP-1 page: medication is compounded and dispensed by a licensed third-party pharmacy, and Wellspring Longevity Clinic is not a state-licensed pharmacy nor a drug manufacturer. That is the correct disclosure, stated plainly, and it applies to the longevity shelf too. The legal infrastructure is present and specific — governing law, arbitration venue and a returns and refunds policy all published, which many competitors skip entirely. Three signals point the other way and they are worth taking together rather than separately. No state list is published, so eligibility is an intake question. No legal entity is named beyond the brand, no compounding pharmacy is named and no medical director appears, so there is no one to look up. And the site's own navigation shows leftover generic business-template pages beneath the treatment path — audit, tax and restructuring pages that have nothing to do with a clinic — which makes the site look unfinished. No LegitScript certification is displayed.

Not published, for anything, on any page. Sermorelin, NAD⁺, glutathione, the GLP-1 line and the microdosing option all appear as treatments with descriptive copy and a start button, with cost visible only after intake. For a category where the same molecule ranges widely between sellers, gating price behind a health questionnaire puts the burden entirely on the reader, and it is the main reason to approach this one cautiously rather than because of anything clinical. If you proceed, ask for the monthly cost of the specific molecule, the dose and vial size it covers, and whether the initial provider consultation is billed separately — and read the returns and refunds policy first, since it is published and many competitors have nothing equivalent.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Wellspring's disclosure is accurate and prominent, though the compounding pharmacy itself is never named and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. One presentational issue deserves flagging on a site that otherwise discloses well: naming sermorelin, NAD⁺ and glutathione plainly while marketing semaglutide as "Personalized GLP-1" and tirzepatide as "GLP-1/GIP" means a reader can leave the weight-loss pages without knowing which molecule they would be taking. On the evidence, the longevity shelf runs from thin to nonexistent. Sermorelin is a GHRH analog that prompts your own pituitary rather than supplying growth hormone — a real, well-characterized mechanism whose long-term human outcome data stays thin. Injected NAD⁺ has no controlled human outcome trials at all; the forms with human trial data are the oral precursors NR and NMN, and what they demonstrate is a raised blood NAD⁺ level rather than a clinical benefit. Injectable glutathione has essentially no controlled human outcome data behind its detoxification and immunity claims. Individual results vary.